Kenneth S. Koblan
2010
In 2010, Kenneth S. Koblan earned a total compensation of $1.7M as Chief Scientific Officer at Alnylam Pharmaceuticals.
Compensation breakdown
| Non-Equity Incentive Plan | $19,510 |
|---|---|
| Option Awards | $1,263,453 |
| Salary | $248,049 |
| Other | $212,394 |
| Total | $1,743,406 |
Koblan received $1.3M in option awards, accounting for 72% of the total pay in 2010.
Koblan also received $19.5K in non-equity incentive plan, $248K in salary and $212.4K in other compensation.
Rankings
In 2010, Kenneth S. Koblan's compensation ranked 3,481st out of 10,439 executives tracked by ExecPay. In other words, Koblan earned more than 66.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,481 out of 10,439 | 67th |
Division Manufacturing | 1,210 out of 3,838 | 69th |
Major group Chemicals And Allied Products | 235 out of 921 | 75th |
Industry group Drugs | 129 out of 680 | 81st |
Industry Pharmaceutical Preparations | 98 out of 481 | 80th |
Source: SEC filing on May 2, 2011.
Koblan's colleagues
We found five more compensation records of executives who worked with Kenneth S. Koblan at Alnylam Pharmaceuticals in 2010.
2010
Laurence Reid
Alnylam Pharmaceuticals
Senior Vice President and Chief Business Officer
2010
John Maraganore
Alnylam Pharmaceuticals
Chief Executive Officer
2010
Barry Greene
Alnylam Pharmaceuticals
Chief Operating Officer
2010
Akshay Vaishnaw
Alnylam Pharmaceuticals
Senior Vice President, Clinical Research
2010
Patricia Allen
Alnylam Pharmaceuticals